A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
Clinical trial NCT06311383 · COMPLETED
Trial details
- NCT number
- NCT06311383
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2017-10-09
- Primary completion
- 2025-03-10
- Enrollment
- 2610
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.